KR900014595A - 태반 단백질 9(PP9)의 암호화 cDNA, 이의 분리방법 및 용도 - Google Patents

태반 단백질 9(PP9)의 암호화 cDNA, 이의 분리방법 및 용도 Download PDF

Info

Publication number
KR900014595A
KR900014595A KR1019900003102A KR900003102A KR900014595A KR 900014595 A KR900014595 A KR 900014595A KR 1019900003102 A KR1019900003102 A KR 1019900003102A KR 900003102 A KR900003102 A KR 900003102A KR 900014595 A KR900014595 A KR 900014595A
Authority
KR
South Korea
Prior art keywords
dna
rna
rna according
diagnostic aid
diagnostic
Prior art date
Application number
KR1019900003102A
Other languages
English (en)
Inventor
그룬트만 울리히
Original Assignee
스타인, 부그
베링베르케 아크엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타인, 부그, 베링베르케 아크엔게젤샤프트 filed Critical 스타인, 부그
Publication of KR900014595A publication Critical patent/KR900014595A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

태반 단백질 9(PP9)의 암호화 cDNA, 이의 분리방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 람다 gt11-362와 관련하여 다이아그램으로 도시된 λgt11-10의 배치도이다.

Claims (16)

  1. 표 1에 나타낸 아미노산 서열을 암호화하는 DNA서열, 이의 대립형질체 및 변이체.
  2. 표 1에 나타낸 암호화 쇄를 함유하는, 태반-특이 단백질 PP9의 암호화 DNA 서열.
  3. 엄격한 조건하에서, 제1항에 따른 DNA와 하이브리드화하는 DNA 또는 RNA.
  4. 제1항 내지 3항중 어느 한항에 따른 DNA 또는 RNA를 함유하는 유전자 구조물.
  5. 제1 내지 4항중 어느 한 항에 따른 DNA 또는 RNA를 함유하는 벡터.
  6. 제1 내지 5항중 어느 한 항에 따른 DNA 또는 RNA를 함유하는 형질전환된 세포.
  7. 제2항에 따른 DNA서열을 이.콜라이, 효모 또는 동물세포중에서 발현시켜 유전공학적으로 제조된 PP9.
  8. 제1항 내지 4항중 어느 한 항에 따른 cDNA 또는 RNA를 발현 시스템내에 도입시키고 발현시킴을 특징으로 하여, PP9를 제조하는 방법.
  9. 유전공학적으로 제조된 PP9또는 항원활성을 갖는 이의 단편으로 면역시켜 수득한, PP9에 대해 특이성인 폴리클로날 또는 모노클로날 항체.
  10. 제1항 내지 4항중 어느 한 항에 따른 DNA 또는 RNA를 전체적으로 또는 부분적으로 함유하는 진단 보조제.
  11. 제9항에 따른 항체를 함유하는 진단 보조제.
  12. 체액, 조직 또는 이들로부터 분리된 핵산을 제10항 또는 제11항에 따른 진단 보조제와 접촉시킴을 특징으로 하는 진단법.
  13. 약제로서의 PP9.
  14. PP9를 함유하는 약제.
  15. 제7항에 따른 PP9를 사용함을 특징으로 하는, 알도스 리덕타제 억제제의 검출방법 또는 스크리닝 방법.
  16. 알도스 리덕타제 억제제를 스크리닝 또는 검출하기 위한 제7항에 따른 PP9의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900003102A 1989-03-10 1990-03-09 태반 단백질 9(PP9)의 암호화 cDNA, 이의 분리방법 및 용도 KR900014595A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3907744A DE3907744A1 (de) 1989-03-10 1989-03-10 Fuer das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung
DEP3907744.6 1989-03-10

Publications (1)

Publication Number Publication Date
KR900014595A true KR900014595A (ko) 1990-10-24

Family

ID=6375984

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900003102A KR900014595A (ko) 1989-03-10 1990-03-09 태반 단백질 9(PP9)의 암호화 cDNA, 이의 분리방법 및 용도

Country Status (11)

Country Link
EP (1) EP0386733B1 (ko)
JP (1) JPH02295486A (ko)
KR (1) KR900014595A (ko)
AT (1) ATE124722T1 (ko)
AU (1) AU625082B2 (ko)
CA (1) CA2011877A1 (ko)
DE (2) DE3907744A1 (ko)
DK (1) DK0386733T3 (ko)
ES (1) ES2076238T3 (ko)
IE (1) IE67797B1 (ko)
PT (1) PT93381B (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2680229B2 (ja) * 1992-02-12 1997-11-19 三菱瓦斯化学 株式会社 人アルドース還元酵素の測定方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013724A1 (de) * 1980-04-10 1981-10-15 Behringwerke Ag, 3550 Marburg Neues protein pp (pfeil abwaerts)9(pfeil abwaerts), verfahren zu seiner anreicherung und gewinnung sowieseine verwendung

Also Published As

Publication number Publication date
EP0386733A1 (de) 1990-09-12
DE59009360D1 (de) 1995-08-10
ES2076238T3 (es) 1995-11-01
CA2011877A1 (en) 1990-09-10
DE3907744A1 (de) 1990-09-20
AU625082B2 (en) 1992-07-02
PT93381A (pt) 1990-11-07
IE900853L (en) 1990-09-10
ATE124722T1 (de) 1995-07-15
PT93381B (pt) 1996-02-29
JPH02295486A (ja) 1990-12-06
IE67797B1 (en) 1996-05-01
AU5110390A (en) 1990-09-13
DK0386733T3 (da) 1995-11-20
EP0386733B1 (de) 1995-07-05

Similar Documents

Publication Publication Date Title
Flach et al. The transition from maternal to embryonic control in the 2‐cell mouse embryo.
Brady et al. Recombinant expression and localization of Schistosoma mansoni cathepsin L1 support its role in the degradation of host hemoglobin
Sekimizu et al. Purification and preparation of antibody to RNA polymerase II stimulatory factors from Ehrlich ascites tumor cells
Alger et al. Molecular and enzymatic characterisation of Schistosoma mansoni thioredoxin
KR870010189A (ko) HTLV-Ⅲgag/ env 유전자 단백질의 발현 및 정제
CA2413857A1 (en) Pd-l2 molecules: pd-1 ligands and uses therefor
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
Michaeli et al. Localization of antigenic determinants in the polypeptide chains of collagen
Rook et al. The role of oil and agalactosyl IgG in the induction of arthritis in rodent models
BR0306979A (pt) Polipeptìdeo isolado, proteìna de fusão, molécula isolada de polinucleotìdeo, vetor de expressão, célula cultivada, anticorpo ou fragmento de anticorpo, e, métodos para produzir uma proteìna, para produzir um anticorpo, para estimular uma resposta imune em um mamìfero, para expandir células hematopoiéticas e progenitores de células hematopoiéticas, para detectar a presença de rna zcytor17lig e de zcytor17lig em uma amostra biológica, para matar cérlulas cancerìgenas, para inibir a proliferação induzida por zcytor17lig ou diferenciação de células hematopoiéticas e progenitoras de células hematopoiéticas, para reduzir a inflamação induzida por zcytor17lig para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero acometido por uma doença inflamatória e para detectar inflamação em um paciente
EP0611394A1 (en) Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
NO911688D0 (no) Neurotrophin-3, en ny neurotrofisk faktor relatert til neurovekstfaktor og hjerne-avledet neurotrofisk faktor.
Nathanson et al. Regulated expression and intracellular localization of cystatin F in human U937 cells
RU2218181C2 (ru) ЧЕЛОВЕЧЕСКИЙ СЕМАФОРИН L(H-Sema-L) И СООТВЕТСТВУЮЩИЕ СЕМАФОРИНЫ В ДРУГИХ ВИДАХ
WO1989009222A1 (en) Cloned human topoisomerase i
Azen et al. Polymorphism of Ps (parotid size variant) and detection of a protein (PmS) related to the Pm (parotid middle band) system with genetic linkage of Ps and Pm to Gl, Db, and Pr genetic determinants
RU98112759A (ru) Человеческий семафорин l (h-sema-l) и соответствующие семафорины в других видах
KR890008317A (ko) 유전학적 조작에 의한 응고억제성 단백질 pp4의 제조방법
KR900014595A (ko) 태반 단백질 9(PP9)의 암호화 cDNA, 이의 분리방법 및 용도
DE69433902D1 (de) Neuartige tyrosinkinase
Strand et al. Development and partial characterization of monoclonal antibodies to venom of the parasitoid Microplitis demolitor
Waseem et al. Conformational changes in the rod domain of human keratin 8 following heterotypic association with keratin 18 and its implication for filament stability
Brinet et al. Anti-histone antibodies (ELISA and immunoblot) in canine lupus erythematosus.
EP0293827A3 (en) Assay for leishmaniasis
DE69316388T2 (de) CRF Bindungsproteine

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application